首页> 美国卫生研究院文献>other >Does Anticoagulant Medication Alter Fracture-Healing? A Morphological and Biomechanical Evaluation of the Possible Effects of Rivaroxaban and Enoxaparin Using a Rat Closed Fracture Model
【2h】

Does Anticoagulant Medication Alter Fracture-Healing? A Morphological and Biomechanical Evaluation of the Possible Effects of Rivaroxaban and Enoxaparin Using a Rat Closed Fracture Model

机译:抗凝药物会改变骨折愈合吗?使用大鼠闭合骨折模型对利伐沙班和依诺肝素可能作用的形态学和生物力学评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Low molecular weight heparin (LMWH) is routinely used to prevent thromboembolism in orthopaedic surgery, especially in the treatment of fractures or after joint-replacement. Impairment of fracture-healing due to increased bone-desorption, delayed remodelling and lower calcification caused by direct osteoclast stimulation is a well-known side effect of unfractioned heparin. However, the effect of LMWH is unclear and controversial. Recent studies strongly suggest impairment of bone-healing in-vitro and in animal models, characterized by a significant decrease in volume and quality of new-formed callus. Since October 2008, Rivaroxaban (Xarelto) is available for prophylactic use in elective knee- and hip-arthroplasty. Recently, some evidence has been found indicating an in vitro dose independent reduction of osteoblast function after Rivaroxaban treatment. In this study, the possible influence of Rivaroxaban and Enoxaparin on bone-healing in vivo was studied using a standardized, closed rodent fracture-model. 70 male Wistar-rats were randomized to Rivaroxaban, Enoxaparin or control groups. After pinning the right femur, a closed, transverse fracture was produced. 21 days later, the animals were sacrificed and both femora harvested. Analysis was done by biomechanical testing (three-point bending) and micro CT. Both investigated substances showed histomorphometric alterations of the newly formed callus assessed by micro CT analysis. In detail the bone (callus) volume was enhanced (sign. for Rivaroxaban) and the density reduced. The bone mineral content was enhanced accordingly (sign. for Rivaroxaban). Trabecular thickness was reduced (sign. for Rivaroxaban). Furthermore, both drugs showed significant enlarged bone (callus) surface and degree of anisotropy. In contrast, the biomechanical properties of the treated bones were equal to controls. To summarize, the morphological alterations of the fracture-callus did not result in functionally relevant deficits.
机译:低分子量肝素(LMWH)通常在整形外科中用于预防血栓栓塞,尤其是在骨折的治疗中或在关节置换后。由直接破骨细胞刺激引起的骨解吸增加,延迟重塑和钙化程度降低引起的骨折愈合不良是未分级肝素的众所周知的副作用。但是,LMWH的作用尚不清楚,也存在争议。最近的研究强烈建议在体外和在动物模型中对骨愈合的损害,其特征在于新生愈伤组织的体积和质量显着降低。自2008年10月起,利伐沙班(Xarelto)可用于预防性膝关节置换术和髋关节置换术。最近,已经发现一些证据表明利伐沙班治疗后成骨细胞功能的体外剂量依赖性降低。在这项研究中,利伐沙班和依诺肝素对体内骨愈合的可能影响是使用标准化的闭合性啮齿动物骨折模型研究的。将70只雄性Wistar大鼠随机分为利伐沙班,依诺肝素或对照组。固定右股骨后,产生闭合的横向骨折。 21天后,处死动物并收获两只股骨。通过生物力学测试(三点弯曲)和微型CT进行分析。两种被调查物质均显示了通过显微CT分析评估的新形成愈伤组织的组织形态变化。详细地,骨头(愈伤组织)的体积增加了(利伐沙班的迹象)并且密度降低了。骨矿物质含量相应增加(利伐沙班的迹象)。骨小梁厚度减少(利伐沙班的迹象)。此外,两种药物均显示出明显的增大的骨(愈伤组织)表面和各向异性程度。相反,处理过的骨骼的生物力学性能与对照相同。总而言之,骨折fracture的形态改变并未导致功能相关的缺陷。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号